Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 1
2015 1
2016 1
2017 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM. Drilon A, et al. Among authors: wollenberg la. Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3. Cancer Discov. 2017. PMID: 28578312 Free PMC article. Clinical Trial.
An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614).
Wollenberg LA, Corson DT, Nugent CA, Peterson FL, Ptaszynski AM, Arrigo A, Mannila CG, Litwiler KS, Bell SJ. Wollenberg LA, et al. Clin Pharmacol. 2015 Sep 30;7:87-95. doi: 10.2147/CPAA.S83871. eCollection 2015. Clin Pharmacol. 2015. PMID: 26491375 Free PMC article.